FDA.reportPublic FDA data

nivolumab-hyaluronidase-nvhy 600 MG / 10,000 UNT per 5 ML Injection

RxCUI
2700798
RxNorm name
nivolumab-hyaluronidase-nvhy 600 MG / 10,000 UNT per 5 ML Injection
Display name
nivolumab-hyaluronidase-nvhy 600 MG / 10,000 UNT per 5 ML Injection
Full name
nivolumab-hyaluronidase-nvhy 600 MG / 10,000 UNT per 5 ML Injection
Term type
SY
Status
DailyMed mapping
Updated
2026-06-04 23:39:05

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761381Opdivo Qvantignivolumab and hyaluronidase-nvhy351(a)Rx2026-08-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
OPDIVO QVANTIGNIVOLUMAB AND HYALURONIDASE-NVHYE.R. Squibb & Sons, L.L.C.7f8c38fa-42f4-4387-9e8c-7a1c66855d8b2026-05-12Warnings, Adverse reactionsExact identifier
rxcui: 2700798

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
7f8c38fa-42f4-4387-9e8c-7a1c66855d8bnivolumab-hyaluronidase-nvhy 600 MG / 10,000 UNT in 5 ML Injection [PSN] · 5 ML hyaluronidase-nvhy 2000 UNT/ML / nivolumab-nvhy 120 MG/ML Injection [SCD] · nivolumab-hyaluronidase-nvhy 600 MG / 10,000 UNT per 5 ML Injection [SY]38These highlights do not include all the information needed to use OPDIVO QVANTIG safely and effectively. See full prescribing information for OPDIVO QVANTIG. OPDIVO QVANTIG™ (nivolumab and hyaluronidase-nvhy) injection, for subcutaneous use. Initial U.S. Approval: 202420260512